BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:20 PM
 | 
Mar 04, 2010
 |  BC Extra  |  Top Story

Apixaban meets VTE endpoint

Bristol-Myers Squibb Co. (NYSE:BMY) and partner Pfizer Inc. (NYSE:PFE) reported that apixaban was superior to Lovenox enoxaparin on the primary endpoint in the Phase III ADVANCE-2 trial to prevent venous thromboembolism (VTE) in patients undergoing knee replacement surgery. Apixaban was superior to Lovenox on...

Read the full 219 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >